The Utilisation of RWE to Meet Emerging Market Access Challenges: Exclusive New Interview Released with PAREXEL

SMi Group speak to workshop hosts PAREXEL in the run up to 23rd annual industry summit on Pharmaceutical Pricing & Market Access.

London, United Kingdom, July 28, 2017 --( With over five years’ experience at PAREXEL, Richard Macaulay is Principal Consultant with expertise in a range of pricing and market access strategy. Richard is a recognized thought leader with an interest in how oncology drugs can receive regulatory approval and payer reimbursement in Europe and the US based on clinical trial packages lacking phase III data.

Hear more from Richard at SMi’s 23rd Annual conference on Pharmaceutical Pricing and Market Access where he will be providing hands on training in a pre-conference interactive workshop on using real world evidence (RWE).

The workshop co-hosted with Janice Haigh, VP Pricing & Market Access; and Oliver Leatham, Vice President, Global Head of Pricing & Market Access, will explore RWE as a tool to fill the evidentiary gap between regulators and payers and in turn, obtain faster reimbursement. It will address challenges in how data is collected, analysed and utilized in payer decision-making and also include presentations from HTA payer bodies to provide their perspective on how RWE can be best utilized to meet common industry hurdles.

In the run up to the show, SMi Group caught with Richard to discuss industry developments and his upcoming presentation. From the answers provided, it is apparent that a number of challenges still remain for the industry to achieve efficient reimbursement and for patients to gain access to affordable medication.

“Payers are demanding increasingly robust evidence packages to justify price premiums whilst regulators are introducing expedited programs that lower the evidence benchmark for approval, making pricing assessments challenging.” -Richard Macaulay, Parexel

“Appropriate pricing and reimbursement of new transformational medicines approved under expedited regulatory pathways where data indicates the potential for dramatic patient benefits but where considerable uncertainty remains will necessitate increasing utilisation of alternative reimbursement mechanisms. In the future, there will an increasing move from traditional forms of reimbursement towards a greater acceptance and utilisation of such innovative contracting arrangements, including performance-based reimbursement, indication-specific pricing, dynamic pricing, and leasing.” -Richard Macaulay, Parexel

The full interview is available to read in the event download centre at

SMi’s 23rd annual conference on Pharmaceutical Pricing & Market Access will take place on 11th & 12th October at the Holiday Inn Kensington Forum in London, UK.

Further details are available online at

Contact Information:

For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email:

For all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at
SMi Group
Teri Arri
+44 (0) 207 827 6102